Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas and CoMentis to collaborate on beta-secretase inhibitors
Upon closing, CoMentis will receive an upfront payment of $80 million and an equity investment of $20 million. CoMentis has the opportunity to receive up to $660 million
Upon closing, CoMentis will receive an upfront payment of $80 million and an equity investment of $20 million. CoMentis has the opportunity to receive up to $660 million
The CHMP decision is based on data from two well-controlled clinical trials that evaluated the efficacy and safety of Neupro over a six month period in almost 1,000
Ondansetron Injection is an antiemetic and is indicated for the prevention of nausea and vomiting associated with cancer chemotherapy and postoperative conditions. Arthur Przybyl, president and CEO of
Shire is making a payment to Zymenex of $135 million for the acquisition of global rights to the product upon completion of the transaction, which is conditional upon
The Phase I trial (study 104) in 30 healthy volunteers has two parts: A Single-dose, three-way crossover study in 12 healthy volunteers measuring pharmacokinetics, safety and tolerability of
Under the recently executed material transfer agreement, BioCure will utilize ImmuneRegen’s Homspera for the development of a combination product composed of the potential wound-healing therapeutic Homspera and BioCure’s
Dyax will receive a $15 million upfront payment, an additional $2.5 million milestone payment in 2008 and is eligible to receive up to an additional $214 million in
The merger is part of a streamlining of the two companies in which Arrowhead assumed active management to increase efficiency and focus resources on bringing multiple products to
This Phase I study is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. The study is
This trial, which will enroll a total of 15 patients, is designed to evaluate the safety and to observe the efficacy trend of Cortiject. The patients will be